Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPTAT: Azacitidine followed by allo-HSCT for TP53-positive MDS
jRCT1051200003Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and refractory anemia with excess blasts in transformation (RAEB-T), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year overall survival after allo-HSCT. Started Nov 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)refractory anemia with excess blasts in transformation (RAEB-T)
Beyond the preview
Go deeper on jRCT1051200003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051200003.